Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Noul Demonstrates AI-Driven On-Site Diagnostics Platform at MEDICA 2022

By LabMedica International staff writers
Posted on 15 Nov 2022

Noul Co. More...

, Ltd. (Gyeonggi-do, Korea) is demonstrating the world’s first integrated device featuring fully-automated sample preparation and AI-based diagnosis at the 2022 edition of MEDICA being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Noul is demonstrating miLab, which is the world’s first all-in-one, fully-automated device which can process sample preparation and AI diagnostic in one workflow. miLab integrates cutting edge technologies from computer vision AI, bio, hardware and software engineering. From automated sample preparation to imaging and AI analysis, the miLab platform combines the gold standard in blood diagnostics into a fully automated benchtop platform. Combined with embedded AI and the company’s patented Next Generation Staining and Immunostaining (NGSI) cartridges, miLab provides an accurate analysis in 20 minutes using just 5 uL of blood. NGSI, the patented solid-based staining technology can replace the current liquid-based sample preparation methods and possess the potential to expand applicabilities to other diagnostic areas. NGSI technology eliminates the liquid usage in the sample staining process and can complete it in only a few minutes using a single step stamping method.

miLab provides superior accuracy compared to the competing technologies by combining multi-focus imaging and the state-of-the-art AI algorithm. The company’s AI can perfectly replicate the diagnosis of an expert microscopist without the errors and deviations. miLab’s AI algorithm analyzes multi-layered digital images of smeared blood cells to achieve 99%+ specificity in order to classify and detect parasite-infected cells. Among Noul’s offerings is the miLab Malaria which detects different stages of Plasmodium Falciparum and Plasmodium Vivax species and the miLab BCM which provides a morphology-based white blood cell (WBC) differential and cell count estimations, allowing decentralized health facilities to perform a WBC differential count and CBC estimation.

Related Links:
Noul Co., Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.